Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation.
Arjun Datt LawSita BhellaIvan PasicWilson LamFotios V MichelisArmin GerbitzAuro ViswabandyaRajat KumarJeffrey H LiptonJonas MattssonDennis Dong Hwan KimPublished in: Annals of hematology (2021)
Avascular necrosis (AVN) is a debilitating complication of allogeneic hematopoietic cell transplantation (HCT). A retrospective review of 845 patients who underwent HCT was conducted. Cumulative incidence of AVN was 6.3% at 4 years. The following risk factors were significantly associated with AVN risk on univariate analysis: age < 45 (p=0.004), moderate to severe chronic GvHD (p<0.001), reduced intensity conditioning (p=0.02), and a diagnosis of acute leukemia (p=0.045). Multivariate analysis confirmed two risk factors: younger age (<45 years), 9.0% vs 4.4% (p=0.011, hazard ratio (HR) 2.134), and moderate-severe chronic GvHD, 15.4% vs 2.1% (p<0.001, HR 4.950). A risk score model was generated assigning a score to each risk factor. A score of 1 was assigned to moderate-severe GvHD or those with age <45. Total score was calculated, thus dividing patient into three groups: low (score 0, n=349, 41.3%), intermediate (score 1, n=379, 44.9%), and high risk (score 2; n=116, 13.7%). This risk score could stratify the patients according to AVN risk (p<0.001). The risk of AVN was 1.5% in the low risk, 6.2% in the intermediate risk, and 20.8% in the high risk groups. Moderate-severe chronic GvHD and younger age (<45 years) are key risk factors for AVN following allogeneic HCT.
Keyphrases
- risk factors
- high intensity
- end stage renal disease
- stem cell transplantation
- early onset
- patients undergoing
- ejection fraction
- bone marrow
- newly diagnosed
- drug induced
- chronic kidney disease
- allogeneic hematopoietic stem cell transplantation
- prognostic factors
- peritoneal dialysis
- acute myeloid leukemia
- signaling pathway
- young adults
- cell cycle arrest
- low dose